Q.Dr. Srinivasan is a senior scientist working for a reputed biotechnology company known for its cutting-edge research in pharmaceuticals. Dr. Srinivasan is heading a research team working on a new drug aimed at treating a rapidly spreading variant of a new viral infectious disease. The disease has been rapidly spreading across the world and the cases reported in the country are increasing. There is huge pressure on Dr. Srinivasan’s team to expedite the trials for the drug as there is significant market for it, and the company wants to get the first-mover advantage in the market. During a team meeting, some senior team members suggest some shortcut for expediting the clinical trials for the drug and for getting the requisite approvals. These include manipulating data to exclude some negative outcomes and selectively reporting positive results, foregoing the process of informed consent and using compounds already patented by a rival company, rather than developing one’s own component. Dr. Srinivasan is not comfortable taking such shortcuts, at the same time he realises meeting the targets is impossible without using these means. A. What would you do in such a situation? B. Examine your options and consequences in the light of the ethical questions involved. C. How can data ethics and drug ethics save humanity at large in such a scenario?

Body Analysis

Stakeholders Involved

• Dr. Srinivasan: The scientist responsible for leading the research team and ensuring ethical drug development.
• Research Team: Pressuring to expedite results, with some proposing unethical methods.
• Biotechnology Company: Eager to gain market advantage by releasing the drug quickly.
• Patients: Depending on the drug for safe and effective treatment.
• Regulatory Authorities: Ensuring clinical trials meet ethical and legal standards.
• Public Trust: The broader population relying on the pharmaceutical industry for integrity and safety.

A. What Would You Do in Such a Situation?

In this scenario, I would reject the unethical shortcuts and adhere strictly to ethical standards in the drug development process. Although it may cause delays, compromising on data integrity, informed consent, or using patented compounds without authorization violates both scientific ethics and legal principles. Instead, I would communicate the risks of unethical practices to my team and management and push for additional resources or time to meet the targets ethically.

B. Options and Consequences in Light of Ethical Questions

1. Proceed with Unethical Shortcuts:

   • Consequences: The drug may be approved faster, but it risks harming patients due to incomplete or manipulated data. If exposed, the company could face severe legal penalties, loss of reputation, and public trust. It may also lead to lawsuits and jeopardize future research.

2. Adhere to Ethical Standards:

   • Consequences: Delaying the drug’s release may lead to market disadvantage and additional pressure from management. However, this ensures patient safety and preserves scientific integrity. In the long run, it maintains the company’s reputation and upholds public trust in pharmaceutical research.

3. Seek Extensions or Additional Resources:

   • Consequences: Requesting more time or resources may mitigate the pressure while maintaining ethical standards. Although the process may still be slower, it ensures compliance with regulatory norms and avoids unethical practices.

C. How Can Data Ethics and Drug Ethics Save Humanity at Large?

• Data Ethics: By ensuring accurate reporting of trial results, data ethics prevent the release of drugs that may have harmful side effects. Data manipulation can lead to unsafe treatments, compromising patient health. Upholding data ethics preserves scientific credibility and ensures that treatments are genuinely safe and effective.
• Drug Ethics: Adhering to drug ethics, including informed consent and respecting intellectual property rights, safeguards public trust and ensures that medical treatments prioritize patient well-being over profit. Compromising on drug ethics can lead to long-term harm, where public confidence in pharmaceutical companies diminishes, affecting global health.

Both data ethics and drug ethics ensure that science serves humanity’s best interest, especially in life-and-death scenarios like pandemics. As Hippocrates said, “First, do no harm,” which must be the guiding principle in all drug development processes.